Abstract
LB1703 High induction dosing of risankizumab in patients with moderate-to-severe plaque psoriasis: Interim results from the phase 2 KNOCKOUT study
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
